First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

BACKGROUND: Programmed cell death 1 (PD-1)-based treatments are approved for several cancers. CheckMate 648, a global, phase 3 trial, showed that first-line nivolumab (anti-PD-1 antibody) plus ipilimumab (NIVO + IPI) or nivolumab plus chemotherapy (NIVO + Chemo) significantly increased survival in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Ken, Doki, Yuichiro, Ogata, Takashi, Motoyama, Satoru, Kawakami, Hisato, Ueno, Masaki, Kojima, Takashi, Shirakawa, Yasuhiro, Okada, Morihito, Ishihara, Ryu, Kubota, Yutaro, Amaya-Chanaga, Carlos, Chen, Tian, Matsumura, Yasuhiro, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024660/
https://www.ncbi.nlm.nih.gov/pubmed/36401133
http://dx.doi.org/10.1007/s10388-022-00970-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024660/
https://www.ncbi.nlm.nih.gov/pubmed/36401133
http://dx.doi.org/10.1007/s10388-022-00970-1

Ejemplares similares